Publication Month: Mar 2023 | Report Code: TIPRE00027647 | No. of Pages: 211 | Category: Biotechnology | Status: Published
Enzymatic DNA synthesis is a well-established technique of DNA synthesis, which is useful in synthetic biology, genetic engineering, therapeutic antibody production, vaccine designing, and other advanced biological procedures. It has also proven helpful in maintaining DNA libraries and synthesizing custom DNA molecules.
Down syndrome, autism spectrum disorder, cancer, diabetes, cystic fibrosis, and sickle cell anemia are a few of the commonly known genetic disorders. Per the Global Genes, more than 10,000 different genetic and rare diseases have been identified, and ~400 million people suffer from rare diseases. Some genetic disorders cause symptoms at birth, while others develop over time. The global burden of genetic diseases appears to be increasing. According to the National Center for Biotechnology Information (NCBI), a US-based medical organization, as of November 2021, genetic disorders were identified in 9.4% of pediatric patients, with 44.7% being critically ill newborns. In addition, 13.17 million patients in the US suffer from unique genetic disorders. According to the Centers for Disease Control and Prevention (CDC) 2022 report, sickle cell disease affects ~100,000 Americans, and it occurs in 1 in 356 African American births. Cystic fibrosis, another common genetic disease worldwide, affects ~30,000 people in the US, and ~1,000 new cases are treated annually. Enzymatic DNA synthesis is a well-established DNA synthesis technique useful in synthetic biology, genetic engineering, and therapeutic antibody studies. In conjunction with enzymatic assays, DNA synthesis shows greater diagnostic possibilities. This method provides important information about people at risk and helps them make important decisions regarding disease diagnosis and medication. Hence, with the rising prevalence of genetic disorders across the world, people are becoming more aware of the need for the early detection of these genetic flaws, which propels the growth of the enzymatic DNA synthesis market
Enzymatic DNA synthesis techniques are not mature enough, and further optimization is required before they are rolled out for widespread use. Most are based on the naturally occurring enzyme terminal deoxynucleotidyl transferase (TdT), which is used in biological systems to add new bases to a DNA sequence. TdT-based method is an improved one over the chemical procedure as it avoids the production of hazardous waste. However, the high costs and low accuracy of this enzyme hinder its use in in vitro DNA synthesis. The TdT enzyme is too permissive, adding wrong bases more often than it should. As a result, TdT-based oligos have more sequence errors and may require the same or even more post-synthesis quality control steps, increasing the time and cost of the synthesis process. While working with this enzyme, scientists need to add more reagents to build their target sequence, which further adds to the cost of the entire synthesis process. The cost per base of synthetic DNA obtained using TdT is much high than conventionally synthesized genetic materials. Thus, high costs and complex procedures limit the growth of the enzymatic DNA synthesis market.
Based on product type, the enzymatic DNA synthesis market is segmented into custom DNA synthesis and DNA library synthesis. The DNA library synthesis segment held the largest market share in 2021. Further, the custom DNA synthesis segment is anticipated to register the highest CAGR during the forecast period (2022–2028).
Get more information on this report :
Based on application, the enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and other applications. The synthetic biology segment held the largest share of the market in 2021. The enzymatic DNA synthesis market for therapeutic antibodies application is expected to grow at the highest CAGR during the forecast period.
Based on end user, the enzymatic DNA synthesis market is segmented into academic & research institutes, biotechnology & pharmaceutical companies, diagnostic laboratories, and others. The biotechnology & pharmaceutical companies segment held the largest share of the market in 2021. The academic & research institutes segment is anticipated to register the highest CAGR in the market during the forecast period (2022–2028).
Based on technology, the enzymatic DNA synthesis market is segmented into SOLA, CRISPR, PCR, and others. The PCR segment has the largest share in 2021 and is expected to continue a similar trend during the forecast period. On the other hand, the CRISPR segment is expected to witness the highest CAGR during the forecast period.
Strategies that are prominently adopted by companies in the enzymatic DNA synthesis market mergers and acquisitions. A few recent developments by key market players are listed below:
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.